Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 9Recruiting 5Terminated 2Withdrawn 1Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Gadolinium × Clear all
NCT00659126 2023-09-07

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

OHSU Knight Cancer Institute

Phase 2 Terminated
40 enrolled 8 charts
CNS

Brain Neoplasms

NCT02057874 2018-07-11

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
2 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡